이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

암 관련 피로를 가진 소아 뇌종양 생존자의 메틸 페니 데이트 (EMBRAIN)

2026년 10월 30일 업데이트: Odense University Hospital

유년기 또는 청소년기 동안 뇌종양 치료를받은 환자의 암 관련 피로에 대한 메틸 페니 데이트의 영향 : 무작위, 이중 맹검, 위약 대조 크로스 오버 시험에 대한 프로토콜-Embrain 시험

Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.

The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).

If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.

연구 개요

연구 유형

중재적

등록 (추정된)

50

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Aalborg, 덴마크, 9000
        • 모병
        • Aalborg University Hospital
        • 연락하다:
          • Christina Friis Jensen, Consultant, MD
          • 전화번호: +45 97663368
          • 이메일: cfj@rn.dk
        • 수석 연구원:
          • Christina Friis Jensen, Consultant, MD
      • Aarhus, 덴마크, 8200
        • 모병
        • Aarhus University Hospital
        • 연락하다:
          • Louise T Henriksen, MD, PhD
          • 전화번호: +45 20921611
          • 이메일: louhen@rm.dk
        • 수석 연구원:
          • Louise T Henriksen, MD, PhD
      • Copenhagen, 덴마크, 2100
        • 모병
        • Rigshospitalet
        • 연락하다:
        • 수석 연구원:
          • Christine Dahl, Consultant, MD, PhD
      • Odense, 덴마크, 5000
        • 모병
        • Odense University Hospital
        • 연락하다:
        • 수석 연구원:
          • Sebastian W Most-Mottelson, MD, PhD Student

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

6년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
  2. Treated for a brain tumor during the previous 10 years.
  3. Age ≥6 years and <28 years at the start of the trial.
  4. Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
  5. No known signs of clinical or radiological tumor progression at last follow-up.
  6. Danish is the sole or primary language (enabling provision of validated assessment tools).
  7. Patient and family have provided consent for inclusion in the trial.
  8. Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
  9. History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.

Exclusion Criteria:

  1. Any known contraindications to methylphenidate as outlined below:

    A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.

  2. History of recent poorly controlled seizures.

  3. Complex tics or Tourette syndrome (including family history of tic disorder).

  4. Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.

  5. Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of <50.

  6. Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.

  7. Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.

  8. Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).

  9. Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Methylphenidate, Then Placebo

Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.

For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.

Dosage will follow the exact same principles as for the study drug (methylphenidate).

실험적: Placebo, Then Methylphenidate

Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.

For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.

Dosage will follow the exact same principles as for the study drug (methylphenidate).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
PedsQL Multidimensional Fatigue Scale (MFS)
기간: At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS).

At baseline, at Week 6, Week 16, and Week 20 (follow-up).

2차 결과 측정

결과 측정
측정값 설명
기간
PedsQL Multidimensional Fatigue Scale (MFS)
기간: At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS.

At baseline, at Week 6, Week 16, and Week 20 (follow-up).
Behaviour Rating Inventory of Executive Function (BRIEF)
기간: At baseline, at Week 6, and Week 16.

Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire.

At baseline, at Week 6, and Week 16.
Connor's Continuous Performance Test (CPT) Online Suite
기간: At baseline, at Week 6, and Week 16.

Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used.

At baseline, at Week 6, and Week 16.
Wechsler Coding
기간: At baseline, at Week 6, and Week 16.

Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant.

At baseline, at Week 6, and Week 16.
Wechsler Digit Span
기간: At baseline, at Week 6, and Week 16.

Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant.

At baseline, at Week 6, and Week 16.
PedsQL Generic Core Scales
기간: At baseline, at Week 6, and Week 16.

Changes from baseline in self and parent-reported measures of Health Related Quality of Life.

At baseline, at Week 6, and Week 16.
Accelerometry (Axivity AX3)
기간: Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.

Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used.

Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
Barkley's Stimulant Side Effect Rating Scale (SSERS)
기간: At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used.

At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Mathias Rathe, Consultant, MD, PhD, Odense University Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 9월 2일

기본 완료 (추정된)

2029년 12월 1일

연구 완료 (추정된)

2029년 12월 1일

연구 등록 날짜

최초 제출

2024년 11월 27일

QC 기준을 충족하는 최초 제출

2025년 3월 25일

처음 게시됨 (실제)

2025년 4월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 30일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다